Phase II Trial of Preoperative Chemotherapy and Bevacizumab in Patients With Stage IIIA Non-Squamous Non-Small Cell Lung Cancer
- Conditions
- on-squamous, Non-small cell lung cancer
- Registration Number
- JPRN-UMIN000004487
- Lead Sponsor
- Osaka International Cancer Institute
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 30
Not provided
1)Active double cancer 2)Current history of hemoptysis 3)Evidence of bleeding diathesis or coagulopathy 4)With great vessel invasion 5)Cavity in tumor 6)History of uncontrollable pericardial effusion 7)History of severe heart disease 8)Current or previous history (within the last 1 year) of symptomatic cerebrovascular disease 9)Active infectious disease in need of intravenous administration of anti-bacterial, anti-fungal, or anti-viral drugs 10)Receiving anticoagulant drug (except Aspirin within 324 mg/day) 11)Uncontrollable Gastrointestinal ulceration 12)Current or previous(within the last 1 year)history of GI perforation 13)Uncontrollable systemic disease (hyper tension or diabetes mellitus) 14)Interstitial pneumonia or pulmonary fibrosis detectable on chest Xp 15)Peripheral neuropathy > Grade2 16)With a history of drug sensitivity 17)History of pregnancy or lactation 18)No intention to practice birth control 19)Patients whose participation in the trial is judged to be inappropriate by the attending doctor
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 3-year disease free survival
- Secondary Outcome Measures
Name Time Method Rate of completion of the protocol treatment Overall survival Disease-free survival clinical and pathologic response Complete resection rate Toxicity Intraoperative and postoperative complications